Leuprolide Completed Phase 3 Trials for Prostate Cancer Treatment

IndicationsStatusPurposePhase
CompletedTreatment3
clinicaltrials.gov IdentifierTitleDrugs
NCT02085252A Study of the Effect of Enantone LP 11.25 mg (Leuprorelin) on the Histological Progression of Indolent Prostate Cancer
NCT00002597Radiation Therapy With or Without Antiandrogen Therapy in Treating Patients With Stage I or Stage II Prostate Cancer
NCT00004635Thalidomide for the Treatment of Hormone-Dependent Prostate Cancer
NCT00193856RADAR Trial - Randomised Androgen Deprivation and Radiotherapy
NCT00295750The Efficacy and Safety of Degarelix One Month Dosing Regimens in Prostate Cancer
NCT00451958A Long-term Extension Study Evaluating a One-Month Dosing Regimen of Degarelix in Prostate Cancer Requiring Androgen Ablation Therapy
NCT00378690A Phase IIIb Study of Intermittent Versus Continuous Hormone Deprivation Treatment With ELIGARD
NCT00076531Clinical Trial for Prostate Cancer
NCT00128531Leuprolide Acetate 3.75 mg Depot to Treat Prostate Cancer
NCT00928434A Study of Degarelix in Patients With Prostate Cancer
NCT00598312Safety and Efficacy Study of Leuprolide Acetate for Injectable Suspension 22.5 MG in the Treatment of Prostate Cancer
NCT00626431A Study of Leuprolide to Treat Prostate Cancer
NCT00003645Randomized Trial of Adjuvant Hormonal Therapy in Surgically Treated Prostate Cancer Patients at High Risk for Recurrence
NCT00003653Hormone Therapy in Treating Patients With Rising PSA Levels Following Radiation Therapy for Prostate Cancer
NCT00002881Flutamide, Suramin, and Hydrocortisone in Treating Patients With Prostate Cancer
NCT00002633Hormone Therapy With or Without Surgery or Radiation Therapy in Treating Patients With Prostate Cancer
NCT01546623A Phase 3 Comparative Study of TAP-144-SR(6M) in Prostate Cancer Patients Previously Treated With Hormonal Therapy
NCT01415960Efficacy and Safety of Leuprolide Acetate 22.5 mg Depot in Treatment of Prostate Cancer